• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Universe Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research Center

    3/22/22 8:00:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email

    Ji'an, Jiangxi, China, March 22, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company has been authorized as an International Branch (the "Branch") of the National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine (the "Center"), a Chinese medicine industry research center approved by the Ministry of Science and Technology of China. As an authorized International Branch, the Company will be allowed to join the Center's strong network and share its extensive industrial recourses, and such authorization demonstrates industry's recognition of the Company's capabilities.

    The Company hosted the authorization ceremony and reception for government and industry representatives on March 11, 2022 in Ji'an, China. Participants of this ceremony included Mr. Xiaodong Zhu, Deputy Mayor of Ji'an government, Mr. Runjin Peng, Mayor of the Ji'an county, Mr. Hui Cao, Director of the Center, Mr. Ming Yang, Professor and Vice President of Jiangxi University of Traditional Chinese Medicine, Mr. Gang Lai, Chairman and CEO of the Company, Mr. Yajun Hu, Vice President of the Company, and Mr. Ichiri Nishimura, Foreign Expert of the Company and Director of the Branch.

    Through leveraging the Center's technologies and utilizing the Company's research and development capacity, the Company has determined to focus its research and development efforts on traditional Chinese medicine, Kampo medicine, Chinese medicine formula granules, and Chinese medicine essential oils. The Company strives to enhance its brand recognition and market position as a pharmaceutical company that serves middle-aged and elderly people.

    Under the guidance of the Center, the Company expects to implement a series of new measures, integrate resources, and improve communications with other biopharmaceutical companies, and the Company intends to make contributions to the internationalization of traditional Chinese medicine.

    Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, "We are excited to be authorized as a Branch from the Center, which is a key milestone for the Company as we are recognized by the experts in the traditional Chinese medicine industry and supported by the Ji'an government. With the integration of resources and support from these parties, we will further work on developing additional types of traditional Chinese medicine and increase our efforts to emerge as a leader in the industry."

    About Universe Pharmaceuticals INC

    Universe Pharmaceuticals INC, headquartered in Ji'an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company's products are sold in 30 provinces of China. For more information, visit the Company's website at http://www.universe-pharmacy.com/.

    Forward-Looking Statements

    All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.

    For more information, please contact:

    Ascent Investors Relations LLC

    Tina Xiao

    President

    Phone: 917-609-0333

    Email: [email protected]



    Primary Logo

    Get the next $UPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Announces Share Consolidation

    Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

    3/20/25 8:30:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

    Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

    2/25/25 4:10:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:20:47 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    2/11/26 4:06:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Universe Pharmaceuticals Inc.

    20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

    1/28/26 7:34:16 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

    SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    1/7/26 3:37:31 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    View All

    Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

    Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

    12/15/21 4:30:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/14/23 2:14:41 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/11/22 8:00:43 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    12/28/21 4:10:53 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care